Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

2020/11/12 by Phillip Monk, Phillip D Monk, Richard J Marsden +47 · 1 citation
Dentistry · Medicine · #COVID-19 Clinical Research Studies #Dental Research and COVID-19 #Infection Control and Ventilation

paper · pdf · doi:10.1016/s2213-2600(20)30511-7

openalex publication_date 2020/11/12 · crossref created 2020/11/12 · crossref issued 2021/02/01 · crossref published 2021/02/01 · crossref published-print 2021/02/01 · openalex created_date 2025/10/10 · crossref deposited 2025/11/01 · crossref indexed 2026/07/24 · openalex updated_date 2026/07/25

Cited by

• The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies